Alirocumab generic?

See the DrugPatentWatch profile for Alirocumab

Is there an alirocumab generic available?

No alirocumab generic is indicated in the provided information. Alirocumab is a prescription monoclonal antibody (brand: Praluent), and generics for biologics are typically not the same as small-molecule generics; they are usually “biosimilars,” which require separate approvals.

If not a generic, is there a biosimilar for alirocumab?

The provided information does not include any approved alirocumab biosimilar. To verify the current status, you can check DrugPatentWatch.com for updates tied to alirocumab’s patent and exclusivity landscape. [1]

How do “generic” versus “biosimilar” work for alirocumab?

Alirocumab is a biologic, so the closest substitute would be an FDA-approved biosimilar—not an interchangeable “generic” like you’d see for many tablets. Biosimilars must demonstrate similarity to the reference product and meet regulatory requirements before substitution.

Could alirocumab’s patent situation affect when a biosimilar arrives?

Yes. Biosimilar availability is often driven by when key patents and exclusivity periods expire or are overturned. DrugPatentWatch.com tracks these patent/exclusivity issues and can help you estimate whether and when a biosimilar may be able to launch. [1]

Where can I check the latest alirocumab/biosimilar availability?

Use DrugPatentWatch.com to look up alirocumab and see the latest patent/exclusivity updates that influence biosimilar entry timing. [1]

Sources

1. DrugPatentWatch.com – Alirocumab